Teladoc Health (NYSE:TDOC) Price Target Lowered to $7.00 at Barclays

Teladoc Health (NYSE:TDOC) had its price target dropped by stock analysts at Barclays from $8.50 to $7.00 in a note issued to investors on Thursday,Benzinga reports. The firm presently has an “equal weight” rating on the health services provider’s stock. Barclays‘s price target would indicate a potential upside of 25.79% from the stock’s previous close.

A number of other analysts also recently issued reports on the stock. Piper Sandler reaffirmed an “overweight” rating and set a $9.00 price objective (down from $12.00) on shares of Teladoc Health in a report on Thursday, February 26th. Leerink Partners lowered their price target on Teladoc Health from $8.50 to $5.50 and set a “market perform” rating on the stock in a research report on Thursday, February 26th. Citigroup dropped their price target on Teladoc Health from $9.00 to $6.00 and set a “neutral” rating for the company in a research note on Tuesday, March 3rd. TD Cowen reduced their price objective on Teladoc Health from $8.00 to $6.00 and set a “hold” rating on the stock in a research report on Thursday, February 26th. Finally, Oppenheimer dropped their target price on Teladoc Health from $12.00 to $7.00 and set an “outperform” rating for the company in a research report on Tuesday, March 3rd. Six equities research analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Teladoc Health presently has a consensus rating of “Hold” and an average target price of $7.64.

Teladoc Health Price Performance

Shares of NYSE TDOC opened at $5.57 on Thursday. The stock’s 50-day simple moving average is $5.32 and its two-hundred day simple moving average is $6.92. Teladoc Health has a twelve month low of $4.40 and a twelve month high of $9.77. The firm has a market capitalization of $992.80 million, a P/E ratio of -4.88 and a beta of 2.13. The company has a quick ratio of 2.67, a current ratio of 2.77 and a debt-to-equity ratio of 0.72.

Teladoc Health (NYSE:TDOC) last issued its quarterly earnings results on Wednesday, February 25th. The health services provider reported ($0.14) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.05. The firm had revenue of $642.27 million during the quarter, compared to the consensus estimate of $635.33 million. Teladoc Health had a negative return on equity of 9.13% and a negative net margin of 7.92%.The company’s revenue for the quarter was up .3% on a year-over-year basis. During the same quarter last year, the company posted ($0.28) EPS. Teladoc Health has set its Q1 2026 guidance at -0.450–0.350 EPS and its FY 2026 guidance at -1.100–0.700 EPS. As a group, equities analysts anticipate that Teladoc Health will post -1.16 EPS for the current fiscal year.

Insider Activity

In other news, CEO Charles Divita III sold 27,731 shares of the firm’s stock in a transaction dated Wednesday, March 11th. The stock was sold at an average price of $5.49, for a total transaction of $152,243.19. Following the transaction, the chief executive officer directly owned 364,784 shares of the company’s stock, valued at approximately $2,002,664.16. This trade represents a 7.06% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 0.58% of the company’s stock.

Hedge Funds Weigh In On Teladoc Health

Several institutional investors and hedge funds have recently bought and sold shares of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Teladoc Health by 2.8% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 193,714 shares of the health services provider’s stock valued at $1,542,000 after purchasing an additional 5,235 shares during the period. NewEdge Advisors LLC raised its holdings in Teladoc Health by 1,278.7% during the 1st quarter. NewEdge Advisors LLC now owns 11,305 shares of the health services provider’s stock valued at $90,000 after buying an additional 10,485 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in Teladoc Health by 5.7% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 447,992 shares of the health services provider’s stock valued at $3,566,000 after buying an additional 24,124 shares during the period. Acadian Asset Management LLC purchased a new stake in Teladoc Health during the 1st quarter valued at $615,000. Finally, Envestnet Asset Management Inc. bought a new stake in Teladoc Health in the 2nd quarter worth $89,000. 76.82% of the stock is currently owned by institutional investors.

About Teladoc Health

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.